Table 2.
Types of organic nanoparticles | Applications | Evaluation models | Administration routes | References | |
---|---|---|---|---|---|
Bilirubin-derived nanoparticles | BRNPs | Hepatic ischemia-reperfusion injury | In vitro in primary mouse hepatocytes; in vivo in mice | Intravenous injection | Kim J. Y. et al., 2017 |
Asthma | In vivo in mice | Intravenous injection; intraperitoneal administration | Kim D. E. et al., 2017 | ||
Inflammatory bowel disease | In vivo in mice | Intravenous injection | Lee et al., 2016a | ||
Pancreatic islet xenotransplantation | In vivo in mice | Intraperitoneal administration | Kim M. J. et al., 2017 | ||
DOX@BRNPs Dox@bt-BRNPs cisPt@BRNPs |
Tumor | In vivo in mice | Intravenous injection | Lee et al., 2016b, 2017, 2018 | |
HABN | Colitis | In vivo in mice | Oral administration | Lee et al., 2020 | |
Melanin-like nanoparticles | MMPP | Acute kidney injury | In vitro in HEK293 cells; in vivo in mice | Intravenous injection | Sun et al., 2019 |
PEG-MeNPs | Ischemic stroke | In vitro in Neuro 2A cells; in vivo in mice | Intravenous injection | Liu et al., 2017 | |
PDA-PEG/CP | Tumor | In vitro in HeLa cells | N/A | Zhu and Su, 2017 | |
Liposome-BSM | Tumor | In vivo in mice | Subcutaneous injection | Chu et al., 2016 | |
PDA NPs | Periodontal disease | In vivo in mice | Subgingival administration | Bao et al., 2018 | |
PDA | Acute peritonitis and acute lung injury | In vivo in mice | Intravenous injection; intraperitoneal administration | Zhao et al., 2018 | |
Free radical-containing organic nanoparticles | RNPN and RNPO | Breast cancer | In vitro in MDA-MB-231 cells; in vivo in mice | Intravenous injection | Shashni and Nagasaki, 2018 |
RNPO | Inflammatory bowel disease | In vivo in mice | Oral administration | Vong et al., 2012, 2014, 2015 | |
RNPN and RNPO | Colon cancer | In vitro in C-26 cells; in vivo in mice | Intravenous injection | Vong and Nagasaki, 2016 | |
RNPN and RNPO | Epidermoid cancers | In vitro in KB-3-1 and KB/MRP cells | N/A | Shashni et al., 2017 | |
RNPN | Radiation-induced organ dysfunctions | In vitro in RAW264.7 cells; in vivo in mice | Subcutaneous injection | Feliciano et al., 2017 | |
RNPN | Ischemia reperfusion injury | In vivo in mice | Intravenous injection | Yoshitomi et al., 2011 | |
RNPs | Nonalcoholic steatohepatitis | In vivo in mice | Intravenous injection | Eguchi et al., 2015 | |
RNPs | Neurological deficits | In vivo in mice | Intravenous injection | Chonpathompikunlert et al., 2012 | |
Phenolic nanoparticles | HPOX | Asthma | In vitro in RAW264.7 cells; In vivo in mice | Intratracheal administration | Yoo et al., 2013 |
Hindlimb ischemia | In vivo in mice | Intramuscular injection | Cho et al., 2015 | ||
H2O2-associated inflammatory diseases | In vitro in RAW264.7 cells | N/A | Cho et al., 2012 | ||
PVAX | Acute liver failure | In vitro in RAW264.7 cells; in vivo in mice | Intravenous injection | Ko et al., 2014 | |
PVO | Hepatic ischemia-reperfusion injure | In vivo in mice | Intravenous injection | Kang et al., 2016 | |
Nanoparticles derived from functional cyclodextrin materials | Nanoparticles based on PBAP-conjugated cyclodextrin | Tumor | In vitro in B16F10 and RAW264.7 cells; in vivo in mice | Intravenous injection | Zhang et al., 2015 |
Arterial restenosis | In vitro in rat VSMCs; in vivo in rats | Intravenous injection | Feng et al., 2016 | ||
Inflammatory bowel disease | In vivo in mice | Oral administration | Zhang Q. et al., 2016 | ||
Atherosclerosis | In vitro in RAW264.7 cells; in vivo in mice | Intravenous injection | Dou et al., 2017 | ||
Abdominal aortic aneurysm | In vivo in mice | Intravenous injection | Cheng et al., 2018 | ||
Peritonitis | In vitro in RAW264.7 cells; in vivo in mice | Intraperitoneal administration | Zhang et al., 2017 | ||
Colitis-associated colon cancer | In vitro in C26 murine colon carcinoma cells; in vivo in mice | Oral administration | Zhang Q. et al., 2019 | ||
LCD nanoparticles | Peritonitis, acute lung injury, and atherosclerosis | In vitro in neutrophils and macrophages; in vivo in mice | Intraperitoneal administration; intravenous injection | Guo et al., 2019 | |
TPCD nanoparticles | Peritonitis, acute lung injury, drug-induced organ toxicity, and atherosclerosis | In vivo in mice | Intraperitoneal administration; intravenous injection | Li et al., 2018; Wang et al., 2018 | |
Other organic nanoparticles | PVA-C | Air pouch model | In vitro in BMSCs; in vivo in rats | Subcutaneous injection | Wu et al., 2019 |